Efficacy and Safety of Vebreltinib in Combination With PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFR Mutations, MET Amplification and/or Overexpression, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Following EGFR-TKI Treatment Failure
Ability to understand and willingness to sign a written informed consent document.
Aged at least 18 years old.
Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB~IV).
At least one measurable lesion as defined by RECIST V1.1.
There are mutations of ALK or ROS1.
Have symptomatic and neurologically unstable central nervous system (CNS) metastases or CNS disease that requires increased steroid doses for control.
Before randomization, patients did not recover from any toxicity and/ or complications of previous chemotherapy, surgery, radiotherapy and other anti-cancer treatments, that is, did not fall to grade 1 or lower (National Cancer Research Common Toxicity Criteria for Adverse Events [NCI-CTCAE] v5.0), except for hair loss and irrecoverable permanent radiation damage.
Major surgery or had significant traumatic injury within 4 weeks prior to the first dose of the investigational product.